Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer

被引：0
|
作者：
Luck, HJ
Thomssen, C
duBois, A
Lisboa, BW
Untch, M
Kuhnle, H
Janicke, F
Meerpohl, HG
Lindner, C
Kcnecny, G
Hecker, D
Diergarten, K
机构：
[1] UNIV MUNICH,MUNICH,GERMANY
[2] ST VINCENTIUS KRANKENHAUSER,FRAUENKLIN,KARLSRUHE,GERMANY
[3] UNIV HAMBURG,FRAUENKLIN EPPENDORF,HAMBURG,GERMANY
[4] UNIV MUNICH,KLINIKUM GROSSHADERN,D-8000 MUNICH,GERMANY
[5] BRISTOL MYERS SQUIBB CO,MUNICH,GERMANY
来源：
SEMINARS IN ONCOLOGY | 1997年 / 24卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S13 / S16
页数：4
相关论文
共 50 条
  • [1] Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer
    Luck, HJ
    Thomssen, C
    duBois, A
    Untch, M
    Lisboa, B
    Kohler, G
    Diergarten, K
    [J]. SEMINARS IN ONCOLOGY, 1997, 24 (05) : 35 - 39
  • [2] Interim analysis of a phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer
    Luck, HJ
    Thomssen, C
    duBois, A
    Lisboa, BW
    Untch, M
    Kuhnle, H
    Konecny, G
    Janicke, F
    Meerpohl, HG
    Lindner, C
    Hecker, D
    Diergarten, K
    [J]. SEMINARS IN ONCOLOGY, 1996, 23 (01) : 33 - 36
  • [3] Preliminary results of a randomized phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer
    Hoelzer, K. L.
    Brufsky, A.
    Hainsworth, J.
    Beck, J. T.
    Whorf, R.
    Keaton, M.
    Kroener, J.
    Krill-Jackson, E.
    Hu, S.
    Bromund, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study
    Einbeigi, Z.
    Bergstrom, D.
    Hatschek, T.
    Malmberg, M.
    [J]. CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2008, 2 : 533 - 538
  • [5] Phase II study of paclitaxel and epirubicin as first-line treatment in patients with metastatic nonsmall cell lung carcinoma
    Ceresoli, GL
    Dell'Oro, S
    Passoni, P
    Villa, E
    [J]. CANCER, 2000, 89 (01) : 89 - 96
  • [6] Paclitaxel, epirubicin and cyclophosphamide combination in first-line treatment of metastatic breast cancer: A dose escalation study
    Bonneterre, J
    Tubiana-Hulin, M
    Catimel, G
    [J]. ONCOLOGY, 2004, 66 (03) : 185 - 191
  • [7] Randomized multicenter phase III study of epirubicin/paclitaxel versus epirubicin/cyclophosphamide in first-line treatment of metastatic breast cancer:: A study of the AGO Breast Cancer Study Group
    Lück, HJ
    Thomssen, C
    Kuhn, W
    Eidtmann, H
    du Bois, A
    Möbus, V
    Untch, M
    Jackisch, C
    Olbricht, S
    Schröder, W
    Richter, B
    Bauknecht, T
    Köhler, C
    Schulz, R
    von Minckwitz, G
    Blohmer, J
    [J]. SEMINARS IN ONCOLOGY, 1999, 26 (06) : 8 - 8
  • [8] Exemestane and Chemotherapy as First-line Treatment of Metastatic Breast Cancer: Results of a Phase II Study
    de la Haba-Rodriguez, Juan
    Gonzalez Mancha, Rosario
    Perez Manga, Gumersindo
    Aranda Aguilar, Enrique
    Baena Canada, Jose Manuel
    Sanchez Rovira, Pedro
    Alba Conejo, Emilio
    [J]. CLINICAL BREAST CANCER, 2010, 10 (04) : 313 - 317
  • [9] A phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer (MBC): Interim safety results
    Brufsky, A. M.
    Hoelzer, K. L.
    Keaton, M. R.
    Beck, J. T.
    Krill-Jackson, E.
    Wang, Y.
    Hu, S.
    Vaughn, L. G.
    Shonukan, O. O.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] First-line treatment with epirubicin and vinorelbine in metastatic breast cancer
    Vici, P
    Colucci, G
    Gebbia, V
    Amodio, A
    Giotta, F
    Belli, F
    Conti, F
    Gebbia, N
    Pezzella, G
    Valerio, MR
    Brandi, M
    Pisconti, S
    Durini, E
    Giannarelli, D
    Lopez, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) : 2689 - 2694
12345